Search results
FDA clears Curio's postpartum depression PDT
NJBIZ· 1 day agoCurio Digital Therapeutics Inc.’s MamaLife Plus offers a nonpharmaceutical alternative to treating postpartum depression. Princeton-based Curio announced...
Healthier Together: Postpartum depression can put new moms, babies at risk
KIRO 7 Seattle-Tacoma· 1 day agoMany doctors and mothers still contend that there’s still a lot of misperceptions and stigma around ...
A New Treatment Offers Hope to Mothers Battling Postpartum Depression
Denton Record-Chronicle· 5 days agoToday, the term for mothers having anxiety and depression after having a baby is called “postpartum ...
An AI blood test purports to diagnose postpartum depression
Washington Post· 6 days agoPostpartum depression is a leading cause of maternal death, but its diagnosis and treatment is spotty at best, negligent at worst. Now ...
Why is a mother’s mental health so important? A doctor explains
Plus via Yahoo News· 4 days agoCNN: What kinds of treatments are available? Wen: Here is the good news. A variety of effective ...
Brooke Shields says adult daughters sleep in the bed with her when husband is away
TODAY via Yahoo News· 3 hours agoBut Shields' journey to motherhood was not easy. She underwent seven rounds of fertility treatments...
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN...
The Herald Journal· 4 days agoLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that dosing of subjects has been completed in the pivotal pharmacokinetic (PK) study designed to support a New Drug ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 days agoPhase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of ...
Reunion raises over $100M to build a better psychedelic drug
BioPharma Dive via Yahoo Finance· 3 days agoThe funding will help Reunion pay for a mid-stage study testing its most advanced medicine —...
HC Wainwright Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $25.00
ETF DAILY NEWS· 6 days agoSage Therapeutics (NASDAQ:SAGE – Free Report) had its target price cut by HC Wainwright from $28.00 to $25.00 in a research report sent to investors on Friday morning, Benzinga reports. They ...